Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

QIAGENs Plattform zur Unterstützung von klinischen Entscheidungsfindungen überschreitet Marke von drei Millionen NGS-Patiententests
QIAGENs Plattform zur Unterstützung von klinischen Entscheidungsfindungen überschreitet Marke von drei Millionen NGS-Patiententests


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass mit QIAGEN Clinical Insights (QCI), der unternehmenseigenen Plattform zur Unterstützung klinischer Entscheidungsfindungen

Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award: https://unsplash.com/photos/WUehAgqO5hE
Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award


Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments Program received a Top Project award for achieving outstanding results in reducing waste. The award

Agilent to Announce Third-Quarter Fiscal Year 2022 Financial Results August 16:
Agilent to Announce Third-Quarter Fiscal Year 2022 Financial Results August 16


Agilent Technologies Inc. (NYSE: A) today announced it will release financial results for the third quarter of fiscal year 2022 after the stock market closes on Tuesday, Aug. 16. The company will

Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with ECU Health (formerly Vidant Health), eastern North Carolina’s premier health system. The new

ECU Health Partners With Acadia Healthcare to Build a New Behavioral Health Hospital Expanding Access to Behavioral Health Services: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
ECU Health Partners With Acadia Healthcare to Build a New Behavioral Health Hospital Expanding Access to Behavioral Health Services


ECU Health and Acadia Healthcare announced today plans to build a state-of-the-art, 144-bed behavioral health hospital in the medical district of Greenville, N.C., less than a mile from ECU Health

Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Dexcom Canada Achieves Great Place to Work® Certification: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Canada Achieves Great Place to Work® Certification


Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by

AMN Healthcare Report: Orthopedic Surgeons Offered the Highest Physician Starting Salary at $565,000
AMN Healthcare Report: Orthopedic Surgeons Offered the Highest Physician Starting Salary at $565,000


Orthopedic surgeons are offered the highest average starting salary among physicians and advanced practice professionals, according to an annual report from AMN Healthcare and its physician search

Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Simulations Plus Realizes Early Success with its Concierge Program: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Realizes Early Success with its Concierge Program


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, recently invested in the creation of their

Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont


Regulatory News:



NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Acadia Healthcare Announces Date for Second Quarter 2022 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Second Quarter 2022 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2022 results on Wednesday, July 27, 2022, after the close of the market. Acadia will conduct a

Extension of the postponement of the settlement of Vifor Pharma tender offer: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Extension of the postponement of the settlement of Vifor Pharma tender offer


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
Premier, Inc. to Report Fiscal 2022 Fourth-Quarter and Full-Year Results and Host Conference Call on August 16, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2022 Fourth-Quarter and Full-Year Results and Host Conference Call on August 16, 2022


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 fourth quarter and full year on Tuesday, August 16, 2022, at approximately 6:30 a.m. ET. The

GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses


GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This

Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2022 financial results on Wednesday, August 3rd, before the market opens. A conference call has been scheduled

Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS